Health

Results: 4885-4896 of 6191

PR Newswire associated0

THERYQ and Gustave Roussy have been selected as part of the "i-Démo" France 2030 call for projects, operated on behalf of the French government by Bpifrance, for the "FLASHDEEP" project, for an amount of 38 million euros

Hansa Biopharma Year-end report January-December 2023

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323

Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

PR Newswire associated0

NABR Files Expanded Petition Challenging the Listing of Long-Tailed Macaques by the IUCN

PR Newswire associated0

Dr. Kaveh Kahen, Appointed President at Phenomenex

Alira Health Releases Global Report on Robotic-Assisted Surgery (RAS) in Orthopedic Procedures

Evaxion Biotech Announces Pricing of $15 Million Public Offering

PR Newswire associated0

New Generative AI Council to Advance Life Sciences Innovation, ArisGlobal Launches GenAI Council with Top Minds from Pharma, Academia, and Technology

Prof. Dean Fennell, Director of the Mesothelioma Research Programme at Leicester University Hospitals in the lab with Dr. Joanna Dzialo and Dr. Aleksandra Bzura. The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung. (Photo: Dan Ryan)

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

PR Newswire associated0

SK chemicals Targets the US Medical Packaging Market with Circular Recycling Solution